BVXV

BiondVax Pharmaceuticals Ltd. [BVXV] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BVXV Stock Summary

In the News

01:10 28 Mar 2024 BVXV

BiondVax to Present at BIO-Europe Spring

JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland. The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.

02:15 28 Mar 2024 BVXV

BiondVax Presenting at BIO CEO & Investor Conference

JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . ( Nasdaq: BVXV ), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the BIO CEO & Investor Conference . The conference is taking place Feb. 6-9, 2023, in New York.

09:28 28 Mar 2024 BVXV

Best Penny Stocks To Buy? 5 To Watch After Big News This Week

Penny stocks to watch with news that are turning heads in the stock market this week. The post Best Penny Stocks To Buy?

06:00 28 Mar 2024 BVXV

BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco

JERUSALEM , Nov. 21, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the January 9-11, 2023 Biotech Showcase conference.

11:30 28 Mar 2024 BVXV

BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference

JERUSALEM , Nov. 3, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Dr. Dalit Weinstein Fischer , BiondVax's Head of Technical R&D, will attend and present at Recent Advances in Fermentation Technology (RAFT) 14, a conference of the Society for Industrial Microbiology and Biotechnology (SIMB) taking place November 6 to 9, 2022 in Orlando, Florida.

07:55 28 Mar 2024 BVXV

BiondVax to Present at LD Micro Investor Conference in Los Angeles

Jerusalem, Israel--(Newsfile Corp. - October 18, 2022) - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Joshua Phillipson, BiondVax's Director of Investor Relations, will attend and present at the LD Micro Main Event XV, an investor conference taking place October 25 to 27, 2022 in Los Angeles.

02:00 28 Mar 2024 BVXV

BiondVax to present at LD Micro Investor Conference in Los Angeles

JERUSALEM , Oct. 11, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Joshua Phillipson, BiondVax's Director of Investor Relations, will attend and present at the LD Micro Main Event XV, an investor conference taking place October 25 to 27, 2022 in Los Angeles.

09:13 28 Mar 2024 BVXV

BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference

JERUSALEM , Sept. 8, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.

06:00 28 Mar 2024 BVXV

BiondVax to Present at this week's Biomed Israel Conference

JERUSALEM  , May 9, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present at the 20th Biomed Israel Conference and Exhibition, to be held May 10-12, 2022, in Tel Aviv, Israel.

03:23 28 Mar 2024 BVXV

BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript

BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript

BVXV Financial details

Company Rating
Neutral
Market Cap
4.97M
Income
7.78M
Revenue
2.02M
Book val./share
-2.1
Cash/share
2.22
Dividend
-
Dividend %
-
Employees
33
Optionable
No
Shortable
Yes
Earnings
29 Nov 2023
P/E
0.59
Forward P/E
-
PEG
-0.05
P/S
2.46
P/B
-0.65
P/C
0.61
P/FCF
-3.53
Quick Ratio
4.05
Current Ratio
4.12
Debt / Equity
-3.46
LT Debt / Equity
-3.41
-
-
EPS (TTM)
2.94
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-6.72%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
11.23%
Inst Trans
0.65%
ROA
39%
ROE
-720%
ROC
-0.48%
Gross Margin
100%
Oper. Margin
-432%
Profit Margin
386%
Payout
-
Shs Outstand
3.65M
Shs Float
2.72M
-
-
-
-
Target Price
-
52W Range
0.63-11.49
52W High
-
52W Low
-
RSI
-
Rel Volume
0.58
Avg Volume
38.94K
Volume
22.67K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
2.36618
-
-
Volatility
0.18%, 0.21%
Prev Close
70%
Price
1.36
Change
60%

BVXV Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0001.950
Net income per share
-35.64-151.986.15-360
Operating cash flow per share
-87.51-94.36-65.46-17.350
Free cash flow per share
-123.82-103.46-70.99-17.650
Cash per share
30.8388.742.6438.280
Book value per share
-12.68-79.66-4.116.530
Tangible book value per share
-12.68-79.66-4.116.530
Share holders equity per share
-12.68-79.66-4.116.530
Interest debt per share
43.86179.0323.2457.080
Market cap
116.29M261.79M100.06M102.96M2232.07B
Enterprise value
121.2M320.61M118.02M118.66M2232.07B
P/E ratio
-4.99-2.1114.68-2.03-4.2M
Price to sales ratio
00037.470
POCF ratio
-2.03-3.4-1.38-4.21-307.24K
PFCF ratio
-1.44-3.1-1.27-4.13-275.53K
P/B Ratio
-14.03-4.02-22.044.41-1.27M
PTB ratio
-14.03-4.02-22.044.41-1.27M
EV to sales
00043.180
Enterprise value over EBITDA
-6.16-4.1733.95-3.66-212.6K
EV to operating cash flow
-2.12-4.16-1.63-4.85-307.24K
EV to free cash flow
-1.5-3.79-1.5-4.76-275.53K
Earnings yield
-0.2-0.470.07-0.490
Free cash flow yield
-0.7-0.32-0.79-0.240
Debt to equity
-3.02-2.02-4.62.99-12.24
Debt to assets
0.891.131.180.70.8
Net debt to EBITDA
-0.25-0.775.17-0.48-0.71
Current ratio
3.533.860.177.646.15
Interest coverage
-5.67-5.250.21-3.222.1
Income quality
0.650.7116.280.611.25
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0008.730
Research and developement to revenue
0003.760
Intangibles to total assets
00000
Capex to operating cash flow
0.410.10.080.020.12
Capex to revenue
000-0.160
Capex to depreciation
-91.27-4.52-2.52-0.18-1.49
Stock based compensation to revenue
0003.240
Graham number
100.85521.9223.81115.710
ROIC
-1.37-1.21-0.28-0.44-0.05
Return on tangible assets
-0.83-1.070.39-0.51-0.02
Graham Net
-25-132.34-17.17-15.590
Working capital
14.62M54.16M-16.66M47.84M12.03M
Tangible asset value
-8.29M-65.05M-4.54M23.33M-1.76M
Net current asset value
-15.99M-107.68M-18.93M-21.22M-14.46M
Invested capital
-3.02-2.02-4.62.99-12.24
Average receivables
1.71M302.61K361.72K340.22K208K
Average payables
5.86M11.28M8.82M1.84M1.91M
Average inventory
-291K-291K000
Days sales outstanding
00040.640
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0008.980
Payables turnover
00000
Inventory turnover
00000
ROE
2.811.91-1.5-2.180.3
Capex per share
-36.31-9.1-5.53-0.30

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0000.620
Net income per share
-6.475.240-1.19-1.11
Operating cash flow per share
-5.5700-0.94-0.85
Free cash flow per share
-5.600-0.95-0.96
Cash per share
21.1515.7603.332.22
Book value per share
2.395.010-1.49-2.1
Tangible book value per share
2.395.010-1.49-2.1
Share holders equity per share
2.395.010-1.49-2.1
Interest debt per share
43.2236.507.297.28
Market cap
76.65M48.58M2232.07B6.99M4.77M
Enterprise value
114.21M81.16M2232.07B19.47M21.87M
P/E ratio
-1.591.2499.7K-0.45-0.32
Price to sales ratio
0003.470
POCF ratio
-7.370140.82K-2.29-1.66
PFCF ratio
-7.340145.31K-2.28-1.46
P/B Ratio
17.165.19-1.27M-1.45-0.67
PTB ratio
17.165.19-1.27M-1.45-0.67
EV to sales
0009.660
Enterprise value over EBITDA
-13.548.19-240.69K-6.39-8.43
EV to operating cash flow
-10.980140.82K-6.37-7.61
EV to free cash flow
-10.930145.31K-6.35-6.72
Earnings yield
-0.160.20-0.55-0.79
Free cash flow yield
-0.1400-0.44-0.68
Debt to equity
17.256.63-12.24-4.84-3.46
Debt to assets
0.90.830.811.24
Net debt to EBITDA
-4.453.29-0.81-4.09-6.59
Current ratio
1.715.756.154.284.12
Interest coverage
-2.960.631.1-9.680
Income quality
0.8100.590.870.76
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0000.990
Intangibles to total assets
00000
Capex to operating cash flow
00-0.0300.13
Capex to revenue
00000
Capex to depreciation
-0.0600.34-0.04-2.56
Stock based compensation to revenue
0000.130
Graham number
18.6624.3106.37.26
ROIC
-0.120.132.99-0.18-0.13
Return on tangible assets
-0.140.130.21-0.17-0.19
Graham Net
-22.03-18.940-5.32-5.74
Working capital
16.61M24.91M12.03M8.47M5.88M
Tangible asset value
4.47M9.36M-1.76M-4.81M-7.11M
Net current asset value
-40.98M-35.2M-14.46M-17.06M-19.24M
Invested capital
17.256.63-12.24-4.84-3.46
Average receivables
622.5K669.5K411.5K114.5K128.5K
Average payables
3.08M1.56M885K1.01M982K
Average inventory
00000
Days sales outstanding
0005.310
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00016.940
Payables turnover
00000
Inventory turnover
00000
ROE
-2.71.05-3.180.80.53
Capex per share
-0.02000-0.11

BVXV Frequently Asked Questions

What is BiondVax Pharmaceuticals Ltd. stock symbol ?

BiondVax Pharmaceuticals Ltd. is a IL stock and trading under the symbol BVXV

What is BiondVax Pharmaceuticals Ltd. stock quote today ?

BiondVax Pharmaceuticals Ltd. stock price is $1.36 today.

Is BiondVax Pharmaceuticals Ltd. stock public?

Yes, BiondVax Pharmaceuticals Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Similar Market Cap